Login / Signup

CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia.

Xin JinRui SunZhu LiXianwu WangXia XiongWenyi LuHairong LyuXia XiaoYunpeng TianHongkai ZhangZhihong FangLuqiao WangMingfeng Zhao
Published in: Haematologica (2024)
Keyphrases
  • acute lymphoblastic leukemia
  • natural killer cells
  • cancer therapy
  • combination therapy
  • drug delivery
  • acute myeloid leukemia
  • nk cells